Semaglutide 2mg

What is Semaglutide (2 mg)?

Semaglutide (2 mg) is a synthetic peptide commonly studied in metabolic and endocrine research. It is a modified version of glucagon-like peptide-1 (GLP-1), a natural hormone that plays a key role in regulating glucose and metabolism.

This peptide has specific amino acid substitutions and a lipid modification that enhance its stability and prolong its interaction with the GLP-1 receptor, making it more suitable for extended studies than native GLP-1, which is rapidly broken down in the body.

In research environments, Semaglutide (2 mg) is used to study hormone-receptor interactions, signaling pathways, and metabolic communication. The 2 mg dosage is ideal for small-scale in vitro studies, pilot experiments, and assay validation that require controlled amounts of peptide.

Product Specifications

• CAS Number: 910463-68-2
• Synonym: NN9535
• Peptide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Weight: 4113.6 g/mol
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 2 mg lyophilized powder in sealed research-grade vial
• Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Semaglutide (2 mg)

• A synthetic GLP-1 receptor agonist analog designed for experimental use
• Structurally modified for enhanced stability in research settings
• Lipid conjugation enables prolonged receptor interaction in vitro
• High analytical purity, confirmed by HPLC and mass spectrometry
• Supplied as lyophilized powder to preserve structural integrity before reconstitution
• Suitable for studies in endocrine, metabolic, and receptor signaling research
• Compatible with standard peptide handling and analytical workflows

How Semaglutide (2 mg) Supports Research

Semaglutide (2 mg) is used in laboratories to study GLP-1 receptor signaling and its role in metabolism. Researchers use this peptide to explore receptor binding, second-messenger activation (like cAMP signaling), and hormone-driven cellular responses under controlled conditions.

Due to its enhanced stability compared to native GLP-1, Semaglutide allows for the study of prolonged receptor engagement and modulation of downstream pathways. It is commonly used in cellular assays, receptor activation studies, and metabolic models to assess endocrine communication and regulatory feedback mechanisms.

Research Applications & Usage Information

Semaglutide (2 mg) is typically used in laboratory and preclinical research focused on:

• GLP-1 receptor activation and binding studies
• Incretin hormone signaling pathway analysis
• Glucose metabolism and insulin regulation studies
• Endocrine system communication research
• Cellular signaling and receptor pharmacodynamics investigations
• Comparative analysis of GLP-1 analogs in controlled experiments

All applications are for investigational use and are limited to in vitro or preclinical laboratory settings.

Handling and Storage Recommendations

• Store at 2–8 °C (≤–20 °C for long-term storage). Protect from light.
• Keep the vial sealed until ready for reconstitution.
• Minimize exposure to moisture and direct light.
• Allow the vial to equilibrate before opening to reduce condensation.
• After reconstitution, store solutions at 2–8 °C according to lab protocols.
• Avoid repeated freeze-thaw cycles to maintain peptide stability.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
2. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7
3. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Published 2019 Apr 12. doi:10.3389/fendo.2019.00155